


Pyronaridine

Cat. No.:	HY-14749
CAS No.:	74847-35-1
Molecular Formula:	C ₂₉ H ₃₂ ClN ₅ O ₂
Molecular Weight:	518.05
Target:	Parasite
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Pyronaridine is an orally active Mannich base anti-malarial agent. Pyronaridine is active against <i>P. falciparum</i> and <i>Echinococcus granulosus</i> infection ^{[1][2]} .								
In Vitro	Pyronaridine (24 h) shows anti- <i>P. falciparum</i> activity with an IC ₅₀ value of 1.53-3.94 nM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	<p>Pyronaridine (57 mg/kg, oral administration, q.d. for 30 days) reduces the parasitic burden in the <i>Echinococcus granulosus</i>-infected mice^[2].</p> <p>Pyronaridine (57 mg/kg, intraperitoneal injection, q.d. for 3 days) reduces the parasitic burden in secondarily infected (cysts) mice^[2].</p> <p>Pyronaridine (57 mg/kg, intraperitoneal injection, for a single dose) exhibits a higher exposure in the liver than in the plasma in male ICR mice^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td><i>Echinococcus granulosus</i>-infected mice model^[2]</td> </tr> <tr> <td>Dosage:</td> <td>57 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration, q.d. for 30 days</td> </tr> <tr> <td>Result:</td> <td>Reduced 42.4% of parasite wet weight and killed 90.7% of secondary infection (cysts) of <i>E. granulosus</i> ss.</td> </tr> </table>	Animal Model:	<i>Echinococcus granulosus</i> -infected mice model ^[2]	Dosage:	57 mg/kg	Administration:	Oral administration, q.d. for 30 days	Result:	Reduced 42.4% of parasite wet weight and killed 90.7% of secondary infection (cysts) of <i>E. granulosus</i> ss.
Animal Model:	<i>Echinococcus granulosus</i> -infected mice model ^[2]								
Dosage:	57 mg/kg								
Administration:	Oral administration, q.d. for 30 days								
Result:	Reduced 42.4% of parasite wet weight and killed 90.7% of secondary infection (cysts) of <i>E. granulosus</i> ss.								

CUSTOMER VALIDATION

- Cell Rep. 2021 Apr 6;35(1):108959.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Jun Li, et al. Old drug repurposing for neglected disease: Pyronaridine as a promising candidate for the treatment of Echinococcus granulosus infections. EBioMedicine. 2020 Apr;54:102711.

[2]. Vivas L, et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop. 2008 Mar;105(3):222-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA